ArticleJournal of biomedical physics & engineering2020
Effect of Neodymium Doping on MRI Relaxivity of Gadolinium Oxide Nanoparticles.
Article in Journal of biomedical physics & engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGadolinium oxide nanoparticles as positive contrast material of magnetic resonance imaging (MRI) have attracted a great attention due to the appropriate magnetic properties. One of the most desirable features of these nanoparticles is their ability of doping with other lanthanides which can change their properties.
objectiveThis study aimed to investigate the effect of neodymium doping on MRI relaxivity of the gadolinium oxide nanoparticles. MATERIAL AND
methodsIn this experimental study, the oleic acid coated gadolinium oxide nanoparticles and the neodymium doped nanoparticles were prepared by polymer pyrolysis method. X-ray diffraction test and scanning electron microscopy were used for characterization of the particles. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to investigate the in vitro cell toxicity of the nanoparticles. The r1 and r2 relaxivities were extracted from the T1 and T2 weighted MR images, respectively.
resultsThe average size of the cytocompatible spherical-like shape nanoparticles was 40 nm. The neodymium doped nanoparticles produced a significant decrease in the r1 relaxivity, and a 1.7 fold increase in the r2 relaxivity compared to the gadolinium oxide nanoparticles.
conclusionDoping of neodymium into the gadolinium oxide nanoparticles suppresses the r1 relaxivity and enhances the r2 relaxivity of the nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.